Published in Mediators Inflamm on June 03, 2009
Adipose tissue dysfunction signals progression of hepatic steatosis towards nonalcoholic steatohepatitis in C57BL/6 mice. Diabetes (2010) 1.43
Alimentary regimen in non-alcoholic fatty liver disease: Mediterranean diet. World J Gastroenterol (2014) 1.30
The role of metformin in the management of NAFLD. Exp Diabetes Res (2011) 1.09
Osteopontin deficiency protects against obesity-induced hepatic steatosis and attenuates glucose production in mice. Diabetologia (2011) 1.07
Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol (2014) 1.07
Time-course microarrays reveal early activation of the immune transcriptome and adipokine dysregulation leads to fibrosis in visceral adipose depots during diet-induced obesity. BMC Genomics (2012) 1.03
Randomized controlled trial to improve adiposity, inflammation, and insulin resistance in obese African-American and Latino youth. Obesity (Silver Spring) (2011) 1.02
High Fat Diet Induces Liver Steatosis and Early Dysregulation of Iron Metabolism in Rats. PLoS One (2013) 0.96
Adipose Tissue Dysfunction and Altered Systemic Amino Acid Metabolism Are Associated with Non-Alcoholic Fatty Liver Disease. PLoS One (2015) 0.95
Inflammatory mediators of hepatic steatosis. Mediators Inflamm (2010) 0.91
Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease. World J Gastroenterol (2014) 0.90
Hepatocellular proliferation correlates with inflammatory cell and cytokine changes in a murine model of nonalchoholic fatty liver disease. PLoS One (2013) 0.90
The Riddle of Nonalcoholic Fatty Liver Disease: Progression From Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis. J Clin Exp Hepatol (2015) 0.89
Immunological mechanisms in the pathophysiology of non-alcoholic steatohepatitis. Int J Mol Sci (2013) 0.89
Saturated fat and cholesterol are critical to inducing murine metabolic syndrome with robust nonalcoholic steatohepatitis. J Nutr Biochem (2014) 0.88
How Much Weight Loss is Effective on Nonalcoholic Fatty Liver Disease? Hepat Mon (2013) 0.88
Metabolic and cardiovascular complications in the liver transplant recipient. Ann Gastroenterol (2015) 0.82
Leptin increases mitotic index and regeneration ratio in hepatectomized rats. Med Sci Monit Basic Res (2013) 0.80
Enhanced A-FABP expression in visceral fat: potential contributor to the progression of NASH. Clin Mol Hepatol (2012) 0.78
Modulation of IKKβ/NF-κB and TGF-β1/Smad via Fuzheng Huayu recipe involves in prevention of nutritional steatohepatitis and fibrosis in mice. Iran J Basic Med Sci (2015) 0.77
Adipocytokines: The pied pipers. J Pharmacol Pharmacother (2010) 0.77
Micronutrient Antioxidants and Nonalcoholic Fatty Liver Disease. Int J Mol Sci (2016) 0.77
Is there any progress in the treatment of non-alcoholic fatty liver disease? World J Gastrointest Pharmacol Ther (2011) 0.76
Hyperreactivity of Blood Leukocytes in Patients with NAFLD to Ex Vivo Lipopolysaccharide Treatment Is Modulated by Metformin and Phosphatidylcholine but Not by Alpha Ketoglutarate. PLoS One (2015) 0.76
Cross talk of the immune system in the adipose tissue and the liver in non-alcoholic steatohepatitis: Pathology and beyond. World J Hepatol (2015) 0.76
Serum γ-glutamyltransferase level is associated with periodontal disease independent of drinking habits in Japanese adults. Med Sci Monit (2014) 0.76
Phosphatase and tensin homolog is a differential diagnostic marker between nonalcoholic and alcoholic fatty liver disease. World J Gastroenterol (2016) 0.76
Serum omentin and vaspin levels in cirrhotic patients with and without portal vein thrombosis. World J Gastroenterol (2017) 0.75
Coffee but not green tea consumption is associated with prevalence and severity of hepatic steatosis: the impact on leptin level. Eur J Clin Nutr (2015) 0.75
Effect of traditional Chinese medicine formula Sinisan on chronic restraint stress-induced nonalcoholic fatty liver disease: a rat study. BMC Complement Altern Med (2017) 0.75
Nonalcoholic fatty liver disease: Diagnostic biomarkers. World J Gastrointest Pathophysiol (2017) 0.75
Adipokine Levels Versus Hepatic Histopathology in Bariatric Surgery Patients. Obes Surg (2017) 0.75
Positional cloning of the mouse obese gene and its human homologue. Nature (1994) 38.85
Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science (1993) 25.54
Nonalcoholic fatty liver disease. N Engl J Med (2002) 22.41
Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology (2004) 18.86
The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology (2005) 15.74
Steatohepatitis: a tale of two "hits"? Gastroenterology (1998) 13.21
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med (2006) 10.97
Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature (2005) 10.10
Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology (2006) 10.05
Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med (2006) 9.53
Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology (2003) 9.36
Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology (2006) 9.34
Obesity-induced inflammatory changes in adipose tissue. J Clin Invest (2003) 7.50
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet (2008) 7.37
Retracted Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science (2004) 7.21
Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science (1996) 6.70
The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest (2003) 5.32
Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med (2000) 4.92
Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr (2006) 4.72
Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity. J Biol Chem (2002) 4.60
Lipotoxic diseases. Annu Rev Med (2002) 4.16
Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology (2003) 4.03
Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol (2008) 4.01
Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology (2004) 3.93
Resistin, an adipokine with potent proinflammatory properties. J Immunol (2005) 3.63
Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology (2007) 3.58
Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology (2005) 3.44
Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology (2004) 3.23
Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun (2003) 3.16
Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin Invest (2003) 3.11
A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology (2004) 3.04
Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology (2002) 2.97
Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol (2006) 2.96
Role of adiponectin in the protective action of dietary saturated fat against alcoholic fatty liver in mice. Hepatology (2005) 2.72
Serum retinol-binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass. Cell Metab (2007) 2.69
Retinol binding protein 4 expression in humans: relationship to insulin resistance, inflammation, and response to pioglitazone. J Clin Endocrinol Metab (2007) 2.58
Influence of TNF gene polymorphisms in Japanese patients with NASH and simple steatosis. J Hepatol (2007) 2.33
Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther (2007) 2.31
Interleukin 6 is important for survival after partial hepatectomy in mice. Hepatology (2003) 2.27
Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway. Biochem Biophys Res Commun (2005) 2.20
A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg (2008) 2.20
Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice. Hepatology (2004) 2.18
Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets. Proc Natl Acad Sci U S A (2000) 2.11
Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol (2007) 2.11
Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology (2002) 2.10
The role of leptin in human obesity and disease: a review of current evidence. Ann Intern Med (1999) 2.05
Serum leptin levels in patients with nonalcoholic steatohepatitis. Am J Gastroenterol (2000) 1.96
Reduction of elevated serum retinol binding protein in obese children by lifestyle intervention: association with subclinical inflammation. J Clin Endocrinol Metab (2007) 1.85
Adiponectin and resistin--new hormones of white adipose tissue. Med Sci Monit (2003) 1.85
Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab (2005) 1.73
Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology (2002) 1.66
Sustained peripheral expression of transgene adiponectin offsets the development of diet-induced obesity in rats. Proc Natl Acad Sci U S A (2003) 1.65
The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis. Semin Liver Dis (2004) 1.62
Adenovirus-mediated chronic "hyper-resistinemia" leads to in vivo insulin resistance in normal rats. J Clin Invest (2004) 1.57
A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol (2004) 1.56
Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut (2005) 1.53
Paradoxical effects of short- and long-term interleukin-6 exposure on liver injury and repair. Hepatology (2006) 1.49
Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals. Hepatology (2001) 1.46
NASH: a mitochondrial disease. J Hepatol (2005) 1.45
Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis. Liver Int (2006) 1.40
Abnormal glucose homeostasis due to chronic hyperresistinemia. Diabetes (2004) 1.39
Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology (2005) 1.34
IL-6-deficient mice are susceptible to ethanol-induced hepatic steatosis: IL-6 protects against ethanol-induced oxidative stress and mitochondrial permeability transition in the liver. Cell Mol Immunol (2004) 1.28
Activation of SOCS-3 by resistin. Mol Cell Biol (2005) 1.27
Adipocytokines and liver disease. J Gastroenterol (2008) 1.25
Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol (2004) 1.24
Expression of adiponectin and its receptors in livers of morbidly obese patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol (2008) 1.24
Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology (2002) 1.24
The evolving role of leptin and adiponectin in chronic liver diseases. Am J Gastroenterol (2006) 1.23
Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J Clin Endocrinol Metab (2006) 1.23
Reactive oxygen intermediates are involved in the induction of CD95 ligand mRNA expression by cytostatic drugs in hepatoma cells. J Biol Chem (1997) 1.17
Hepatic AdipoR2 signaling plays a protective role against progression of nonalcoholic steatohepatitis in mice. Hepatology (2008) 1.17
IL-6 and IGF-1 are independent prognostic factors of liver steatosis and non-alcoholic steatohepatitis in morbidly obese patients. Obes Surg (2007) 1.15
Resistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells. Am J Pathol (2006) 1.14
Serum retinol-binding protein 4 levels are elevated in non-alcoholic fatty liver disease. Clin Endocrinol (Oxf) (2007) 1.13
Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis. Am J Gastroenterol (2007) 1.11
The treatment with antibody of TNF-alpha reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet. Inflammation (2007) 1.10
Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol (2006) 1.10
Transgenic and recombinant resistin impair skeletal muscle glucose metabolism in the spontaneously hypertensive rat. J Biol Chem (2003) 1.10
Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model. J Hepatol (2007) 1.09
Adiponectin gene polymorphisms modulate acute adiponectin response to dietary fat: Possible pathogenetic role in NASH. Hepatology (2008) 1.09
Does leptin play a role in the pathogenesis of human nonalcoholic steatohepatitis? Am J Gastroenterol (2003) 1.08
Possible role of aldehydic lipid peroxidation products as chemoattractants. Int J Tissue React (1987) 1.05
Leptin and liver fibrosis: a matter of fat. Gastroenterology (2002) 1.01
Regulation of fatty acid uptake and metabolism in L6 skeletal muscle cells by resistin. FEBS Lett (2005) 1.00
Interleukin-6 is a key mediator of the hepatoprotective and pro-proliferative effects of ischaemic preconditioning in mice. J Hepatol (2006) 1.00
Influence of visfatin on histopathological changes of non-alcoholic fatty liver disease. Dig Dis Sci (2008) 0.99
Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity. Scand J Gastroenterol (2008) 0.98
Increased production of IL-1alpha and TNF-alpha in lipopolysaccharide-stimulated blood from obese patients with non-alcoholic fatty liver disease. Cytokine (2006) 0.97
New concepts in extracellular signaling for insulin action: the single gateway hypothesis. Recent Prog Horm Res (1997) 0.94
High prevalence of elevated liver enzymes in blood donors: associations with male gender and central adiposity. Eur J Gastroenterol Hepatol (2007) 0.93
Insulin resistance and metabolic syndrome in chronic liver diseases: old entities with new implications. Scand J Gastroenterol (2009) 0.90
Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and non-alcoholic steatohepatitis. Aliment Pharmacol Ther (2007) 0.87
Pattern of expression of adiponectin receptors in human liver and its relation to nonalcoholic steatohepatitis. Obes Surg (2008) 0.86
High molecular weight adiponectin correlates with insulin sensitivity in patients with hepatitis C genotype 3, but not genotype 1 infection. Am J Gastroenterol (2005) 0.84
Adiponectin and alcoholic fatty liver: Is it, after all, about what you eat? Hepatology (2005) 0.77
The burden of incidental findings in clinical practice in a tertiary care center. Eur J Intern Med (2010) 2.70
Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment. J Rheumatol (2008) 2.28
Pylephlebitis: an overview of non-cirrhotic cases and factors related to outcome. Scand J Infect Dis (2010) 1.87
Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection? Hepatology (2008) 1.81
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology (2010) 1.79
Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection. Am J Gastroenterol (2003) 1.75
Risk of hepatocellular carcinoma and extrahepatic malignancies in primary biliary cirrhosis. Eur J Gastroenterol Hepatol (2008) 1.62
Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. Liver Transpl (2005) 1.58
Hepatic granulomas: a 6-year experience in a single center in Greece. Eur J Gastroenterol Hepatol (2007) 1.45
Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis (2007) 1.40
Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment. Semin Liver Dis (2006) 1.40
The evolving role of leptin and adiponectin in chronic liver diseases. Am J Gastroenterol (2006) 1.23
Liver grafts from anti-hepatitis B core positive donors: a systematic review. J Hepatol (2010) 1.23
Adverse drug reactions as a cause of hospital admissions: a 6-month experience in a single center in Greece. Eur J Intern Med (2008) 1.15
Effects of Helicobacter pylori and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: a systematic review. Clin Gastroenterol Hepatol (2006) 1.15
Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl (2008) 1.14
Pseudohyperkalemia in serum: the phenomenon and its clinical magnitude. J Lab Clin Med (2006) 1.12
Pseudohyperkalemia in patients with increased cellular components of blood. Am J Med Sci (2006) 1.09
Strategy to characterize the number and type of repeating EPIYA phosphorylation motifs in the carboxyl terminus of CagA protein in Helicobacter pylori clinical isolates. J Clin Microbiol (2006) 1.07
Pseudohyperkalemia in serum: a new insight into an old phenomenon. Clin Med Res (2008) 1.06
Increasing frequency of Gram-positive bacteria in spontaneous bacterial peritonitis. Liver Int (2005) 0.99
Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring. Antivir Ther (2007) 0.99
MELD vs Child-Pugh and creatinine-modified Child-Pugh score for predicting survival in patients with decompensated cirrhosis. World J Gastroenterol (2005) 0.98
Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity. Scand J Gastroenterol (2008) 0.98
Treatment of HBeAg-negative chronic hepatitis B. Semin Liver Dis (2003) 0.97
Serum apoptotic caspase activity in chronic hepatitis C and nonalcoholic Fatty liver disease. J Clin Gastroenterol (2010) 0.97
Primary aortojejunal fistula due to foreign body: a rare cause of gastrointestinal bleeding. Eur J Gastroenterol Hepatol (2002) 0.94
Pubic osteomyelitis due to Klebsiella pneumoniae in a patient with diabetes mellitus. Am J Med Sci (2006) 0.94
Aspartate aminotransferase to platelet ratio index for fibrosis evaluation in chronic viral hepatitis. Eur J Gastroenterol Hepatol (2006) 0.94
Current treatment indications and strategies in chronic hepatitis B virus infection. World J Gastroenterol (2008) 0.93
EASL clinical practice guidelines on the management of chronic hepatitis B: the need for liver biopsy. J Hepatol (2009) 0.93
Current management of hepatitis B virus infection before and after liver transplantation. Liver Int (2009) 0.92
Substitution treatment or active intravenous drug use should not be contraindications for antiviral treatment in drug users with chronic hepatitis C. Liver Int (2010) 0.91
Predicting utility of a model for end stage liver disease in alcoholic liver disease. World J Gastroenterol (2006) 0.91
Hepatic steatosis in genotype 4 chronic hepatitis C is mainly because of metabolic factors. Am J Gastroenterol (2007) 0.91
Sensorineural hearing loss complicating severe rickettsial diseases: report of two cases. J Infect (2007) 0.90
Insulin resistance and metabolic syndrome in chronic liver diseases: old entities with new implications. Scand J Gastroenterol (2009) 0.90
Primary hepatic actinomycosis. Am J Med Sci (2010) 0.89
Current progress in the treatment of chronic hepatitis C. World J Gastroenterol (2012) 0.87
Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B. J Hepatol (2010) 0.87
Markedly elevated CA 19-9 in the pus and the serum of a patient with pyogenic liver abscess. J Clin Gastroenterol (2006) 0.87
Smoking is associated with steatosis and severe fibrosis in chronic hepatitis C but not B. Scand J Gastroenterol (2009) 0.86
Serum HBV-DNA levels in inactive hepatitis B virus carriers. Gastroenterology (2002) 0.86
A case of liver sarcoidosis mimicking cirrhosis. Clin Imaging (2006) 0.85
Core mutations in patients with acute episodes of chronic HBV infection are associated with the emergence of new immune recognition sites and the development of high IgM anti-HBc index values. J Med Virol (2009) 0.85
Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Transplantation (2003) 0.85
Campylobacter fetus bacteraemia in a healthy individual: clinical and therapeutical implications. J Infect (2005) 0.85
Long-term adefovir plus lamivudine therapy does not decrease creatinine clearance in HBeAg-negative chronic hepatitis B patients. Liver Int (2011) 0.85
Pericarditis and possible antiphospholipid syndrome on primary biliary cirrhosis. Ann Hepatol (2005) 0.84
Angioimmunoblastic T-cell lymphoma-associated arthritis: case report and literature review. J Clin Rheumatol (2005) 0.84
Glucagonoma syndrome: survival 21 years with concurrent liver metastases. Am J Med Sci (2007) 0.84
Treatment of hepatitis B in patients with chronic kidney disease. Kidney Int (2013) 0.83
Simultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C. World J Gastroenterol (2007) 0.83
Peginterferon-alpha2a (40 kDa) for chronic hepatitis C. Expert Opin Pharmacother (2003) 0.83
Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection. Expert Rev Anti Infect Ther (2004) 0.82
Thrombotic risk factors and liver histologic lesions in non-alcoholic fatty liver disease. J Hepatol (2009) 0.82
Ursodeoxycholic acid and histological progression in primary biliary cirrhosis. J Hepatol (2003) 0.81
Precore mutant chronic hepatitis B - approach to management. MedGenMed (2003) 0.81
Danoprevir, a small-molecule NS3/4A protease inhibitor for the potential oral treatment of HCV infection. Curr Opin Investig Drugs (2010) 0.81
Alterations in the proliferating compartment of gastric mucosa during Helicobacter pylori infection: the putative role of epithelial cells expressing p27(kip1). Mod Pathol (2003) 0.80
Interferon alpha-induced hashimoto thyroiditis followed by transient graves disease in a patient with chronic HCV infection. South Med J (2010) 0.80
Subacute thyroiditis presenting as fever of unknown origin in a patient with rheumatoid arthritis under etanercept treatment. J Clin Rheumatol (2010) 0.80
Combined HLA-DR and -DQ disparity is associated with a stable course of ulcerative colitis after liver transplantation for primary sclerosing cholangitis. Liver Transpl (2007) 0.79
Spontaneous bacterial peritonitis in cirrhotic patients: Is prophylactic propranolol therapy beneficial? J Gastroenterol Hepatol (2006) 0.79
Acute Epstein-Barr virus infection in two elderly individuals. Age Ageing (2006) 0.79
Changes of serum levels of keratin-18 fragments in hepatitis B e antigen-negative chronic hepatitis B patients under oral antiviral therapy. Antivir Ther (2011) 0.79
Treatment of HBeAg negative chronic hepatitis B with new drugs (adefovir and others). J Hepatol (2003) 0.78
Increased abdominal fat levels measured by bioelectrical impedance are associated with histological lesions of nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol (2015) 0.78
Dilated cardiomyopathy during the course of hemolytic uremic syndrome. Int J Hematol (2007) 0.78
Usefulness of enzyme-linked immunosorbent assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment. Addendum. J Rheumatol (2008) 0.78
Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients? Liver Int (2015) 0.78
Intracerebral hematoma following intrathecal administration of methotrexate in a patient with non-Hodgkin's lymphoma. Am J Hematol (2005) 0.78
The burden and recent epidemiological changes of the main chronic liver diseases in a Greek referral tertiary centre. Eur J Gastroenterol Hepatol (2010) 0.78
Frequency and predictors of no treatment in anti-hepatitis C virus-positive patients at tertiary liver centers in Greece. Eur J Gastroenterol Hepatol (2013) 0.77
Potential role of apoptosis and apoptotic regulatory proteins in colorectal neoplasia: correlations with clinico-pathological parameters and survival. Dig Dis Sci (2007) 0.77
Naftidrofuryl-induced liver injury. Am J Gastroenterol (2003) 0.77
An extranodal NK/T cell lymphoma, nasal type, with specific immunophenotypic and genotypic features. Int J Hematol (2008) 0.77
HBeAg-negative chronic hepatitis B: why do I treat my patients with pegylated interferon-alfa? Liver Int (2014) 0.77
Adipokines and insulin resistance in chronic hepatitis C. Hepatology (2007) 0.77
Liver involvement in acute vaso-occlusive crisis of sickle cell disease: prevalence and predisposing factors. Scand J Gastroenterol (2007) 0.77
Clinicopathological features and natural history of acute sporadic non-(A-E) hepatitis. J Gastroenterol Hepatol (2008) 0.77
Detection of a hepatitis B surface antigen variant emerging in a patient with chronic lymphocytic leukaemia treated with fludarabine. J Med Virol (2006) 0.77
Primary hepatic actinomycosis mimicking metastatic liver tumor. J Clin Gastroenterol (2010) 0.77
The severity of histologic liver lesions is independent of body mass index in patients with nonalcoholic fatty liver disease. J Clin Gastroenterol (2013) 0.77
Smoking is associated with histological severity in nonalcoholic steatohepatitis. Hepatology (2010) 0.76
Serum markers of hepatocyte apoptosis: current terminology and predictability in clinical practice. Hepatology (2010) 0.76
Emerging treatments in chronic hepatitis B. Expert Opin Emerg Drugs (2004) 0.76